It is promising to target FUBP1 in the treatment of COVID-19 since a study has found that FUBP1 was repressed after SARS-CoV-2 infection in Calu-3 cells, and expression of FUBP1 could be reversed after allicin exposure to SARS-CoV-2-infected cells63. Here, FUBP1 is linked to COVID-19.